MEDP

Does Medpace (MEDP) have what it takes to be a top stock pick for momentum investors? Let's find out.

Medpace (MEDP) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Medpace (MEDP) possesses solid growth attributes, which could help it handily outperform the market.

Medpace (MEDP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Clinical research company Medpace Holdings (NASDAQ:MEDP) met Wall Street’s revenue expectations in Q3 2026, with sales up 8.5% year on year to $716 million.

Medpace’s third quarter saw steady growth, with management attributing performance to robust demand for clinical research services and a healthy pipeline of new business awards.

Medpace Holdings has delivered a powerful multi year run, and with the stock last closing at US$653.96 the obvious question is whether that price still lines up with the cash the business is expected to generate.

Cancellations now stem from clinical failures rather than funding shortages, signaling a healthier market for contract research.

Medpace Holdings (MEDP) just packed several signals into one update. Third quarter earnings topped expectations, 2026 guidance landed below revenue forecasts but ahead on EPS, and a fresh US$1b buyback authorization arrived.

Medpace stock fell Thursday after beating third-quarter forecasts and issuing an above-Street view for 2026 earnings.

Medpace Holdings (NasdaqGS:MEDP) announced a new US$1b share repurchase program running through 2028, replacing its prior authorization.

Record net new business awards and 23.7% net income growth signal strong momentum.